Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $52.00.

KNSA has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. TD Cowen began coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, Citigroup boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer owned 16,666 shares in the company, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Paolini sold 82,542 shares of the business’s stock in a transaction on Friday, October 31st. The stock was sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the sale, the insider directly owned 61,324 shares of the company’s stock, valued at $2,277,573.36. This represents a 57.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 553,057 shares of company stock worth $21,582,372. Corporate insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KNSA. Danske Bank A S bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $1,180,000. Castleark Management LLC purchased a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $6,160,000. PharVision Advisers LLC bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at approximately $261,000. Voleon Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $3,462,000. Finally, Prosperity Wealth Management Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $540,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Down 2.3%

KNSA stock opened at $42.52 on Wednesday. The company’s 50 day moving average is $40.44 and its 200 day moving average is $35.21. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of 94.49 and a beta of 0.02. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.18) EPS. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.